Loading...

Artivion, Inc.

AORTNYSE
Healthcare
Medical - Devices
$32.56
$0.41(1.28%)

Artivion, Inc. (AORT) Stock Overview

Explore Artivion, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.4/100

Key Financials

Market Cap1.4B
P/E Ratio-64.54
EPS (TTM)$-0.51
ROE-0.07%
Fundamental Analysis

AI Price Forecasts

1 Week$28.64
1 Month$31.23
3 Months$33.37
1 Year Target$41.05

AORT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Artivion, Inc. (AORT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 69.40, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $41.05.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -64.54 and a market capitalization of 1.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

69.40RSI (14)
0.70MACD
34.15ADX
Revenue Growth
9.75%
9.75%
Profit Growth
$-0.51
56.47%
EPS Growth
$-0.51
57.33%
Operating Margin
4.03%
577.01%
ROE
-7.31%
56.47%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$30.00
Average$31.00
High$33.00

Company Profile

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

CEO

James Patrick Mackin

Employees

1,600

Headquarters

1655 Roberts Boulevard N.W., Kennesaw, GA

Founded

1993

Frequently Asked Questions

;